icone plus
Contact
Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité DUPIXENT (dupilumab).
See also
Décision d'accès précoce
14/11/2024
eNrlWF1v2jAUfe+vQHl3EqCMMgWqjbUbUqsxWrRpL5WxL2Bm7NQflO7Xz0noRqdEXUP90r2g4I97r+1zzr12crpd88YGlGZS9INmGAcNEERSJhb9YHp9jk6C08FRssIbvDfMjQtbraBBONa6H2S94Qyw0OG3y4sP4OaDCgZHjUTOVkDMo3HWMB5+wnp5idNsTCPZSEYbazBLSftBak3e2ki0US6KwZ1UP3SKCSTRrmW/d3VzvN+eRJmxf7BqNagLLBalRkHUskmsUiDMEBtYSHVfEW+7lm2mJ6ClVQTG2CzHSm4YBVrqYo65hlpO5nf0CtSGg8mclBqPVmStaxnHK7ydwO2oPOh3rndotgbFqNltt9pxt30cN7u9Wq7U3laVn4JbRJTetDuduNftRSAiCoRl4EYCteLWMYpb3TiiJNKwRtSiZowkMXKmoOh2TURyDgtAFBDHaImtAeR+pGImb9RYuI9UKuM+kIK51YgiTAholCrHEfIwV6fOOeb5PJuyrcNQ/sHtGs9qomWc+eWecML08DHUPflRcPskHinTKcf34UqndbcKK+y6QTlB8reQbAXXykkkd3v2l31hOY+eGfV0J2CeIs70cSitMBU6dj6puxFD6XixrT7RetJrtjssMtAvZ/anFOVpZ2xnnJG6Iutk0II208moWmNftzy9xxqmyp8+fWWCyjv98rq3jzNP0ednwkuNpoo2b1q9kzfNTqc2rb87UFdk4TOrZAqRU0SmDxG6kZjLQyXO8aTc1ANLXjFB8upUEsyhoj5FNfXXMeOhnPbGPX+8LjpKjX48u64L2C8W1P1V/rfUNKP931Crl5x8ZDxHj8rAn0+2QnO83FysKteypTGpfhtFS6wLroVzFf4HqW+v/vF3jfNSZBVFZ5E+PIU+K+qCZwCmLuufqsEOvVfs5u/uL6U+jLJwwEEUCcKbjI/OXj4z/LlUeAt7/EjJ/LnJLwDYOGHyVQbaWXkNeFAucucqzpVTh8/zOat4U6vEZRIV73mDoyTK3vIGR78ACuOvJw==
pxnwVycXz2CVuMXV